A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
Status:
Completed
Trial end date:
2015-08-25
Target enrollment:
Participant gender:
Summary
A total of 608 participants with Clostridium Difficile Associated Diarrhea (CDAD) will
participate in this study; participants will receive either oral vancomycin or CB-183,315 in
a blinded fashion. Treatment will last for 10 days and participants will be followed up for
at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well
CB-183,315 treats CDAD as compared to vancomycin.